many patients with long-term, consistently suppressed HIV-1 RNA levels who were receiving stable ART had newly detectable HIV-1 RNA. Systematic review of HIV-1 RNA data suggested an artifact. Assays and specimen processing techniques were compared to determine the cause.
Patients and methods. All patients receiving stable ART with 11 test results demonstrating undetectable HIV-1 RNA by the AMPLICOR ultrasensitive assay during the first quarter of 2007 (1 January through 31 March) and any HIV-1 RNA result by the AmpliPrep/TaqMan assay after 18 June 2007 were identified. All clinical assay testing was performed at a single national reference laboratory. The same inclusion criteria were applied to data from 2006. HIV-1 RNA was considered to be undetectable if levels were below the lower limit of quantitation: 50 copies/mL for the AMPLICOR ultrasensitive assay and 48 copies/mL for the AmpliPrep/TaqMan assay. The Vanderbilt University Institutional Review Board approved the study of additional specimens from a repository and from prospective patients. Statistical analyses were performed using STATA, version 10 (StataCorp). Comparisons between groups were performed using Fisher's exact test.
Results. Of 82 patients with plasma HIV-1 RNA previously undetectable with use of the AMPLICOR ultrasensitive assay, 63 (77%) had detectable HIV-1 RNA levels with use of the AmpliPrep/TaqMan assay after 18 June 2007. Among the 63 patients with newly detectable HIV-1 RNA, measurements for 36 (57%) represented a 10.5-log increase, and measurements for 16 (25%) represented a 11-log increase over the detection threshold of the previous assay. This rate of HIV-1 RNA detectability among persons with previously undetectable HIV-1 RNA was higher ( ) than that for a group of similarly P ! .001 defined patients tested with only the AMPLICOR ultrasensitive assay during both the first quarter of 2006 and June 2006 (9 [10%] of 94 patients had newly detectable HIV-1 RNA during these time periods), which suggested that some of the detectable specimens tested after 18 June 2007 had increased levels of detection because of an artifact.
The hypothesis that the AmpliPrep/TaqMan assay was more sensitive near the lower limit of detection than the AMPLICOR ultrasensitive assay was tested initially. Paired plasma specimens from the Comprehensive Care Center/Vanderbilt-Meharry Center for AIDS Research Specimen Repository were available for 28 patients with discordant results (HIV-1 RNA levels, 50-1330 copies/mL in the assays performed after 18 June 2007). Both the AmpliPrep/TaqMan and AMPLICOR assays were performed on repository specimens collected during both time Flow charts of 2 hypotheses tested to explain artifactual high frequencies of detectable plasma HIV-1 RNA. Phase I tested the hypothesis that the new COBAS AmpliPrep/COBAS TaqMan HIV-1 RNA detection assay (Roche) was more sensitive than the ultrasensitive AMPLICOR assay, version 1.5 (Roche), that was previously used. Paired specimens (processed differently from specimens sent for clinical testing) from the Comprehensive Care Center/Vanderbilt-Meharry Center for AIDS Research Specimen Repository from 28 of the patients whose specimens had yielded discrepant clinical test results were tested at the Vanderbilt Molecular Infectious Diseases Laboratory (MIDL). Similar percentages of detectable HIV-1 RNA were observed with use of the AMPLICOR and AmpliPrep/TaqMan assays. Phase II aimed to confirm whether the artifact was caused by a change to shipment of a frozen primary plasma preparation tube (PPT). Sixteen new patients were enrolled prospectively, and blood was collected in PPTs. Secondary processing for clinical testing with the AmpliPrep/TaqMan assay included decanting plasma into a separate secondary tube for frozen shipment to a national reference laboratory. In addition, a specimen in a primary PPT was frozen for research and was shipped to MIDL, where it underwent AMPLICOR standard (no virion concentration) and ultrasensitive (virion concentration) testing, as well as AmpliPrep/TaqMan testing. Freezing and thawing of the primary PPT was associated with an artifactual high percentage of detectable HIV-1 RNA with all assays. ACD, acid citrate dextrose; Q1, first quarter. We next compared each processing method with use of specimens collected prospectively from 16 patients on stable ART regimens with у2 prior undetectable HIV-1 RNA measurements. Specimens were processed 2 ways after collection in PPTs. Centrifugation and frozen plasma shipment in the primary PPT was compared with frozen plasma shipment in a secondary tube. We also tested whether concentration of virions after thawing and before performing the AMPLICOR assay might minimize the artifacts seen in specimens frozen in primary PPTs. Specimens frozen in the primary PPT from 8 (50%) of 16 patients yielded positive results when tested with the AMPLICOR without virion concentration, and 7 (44%) of 16 of these same specimens had positive results from the AM-PLICOR test after virion concentration. Nine (56%) of 16 of these primary PPT specimens had positive results from the AmpliPrep/TaqMan assay (without virion concentration) ( ). All 16 patients had undetectable HIV-1 RNA from P p .934 clinical testing by AmpliPrep/TaqMan of plasma samples obtained concurrently and shipped in secondary tubes to the reference laboratory, with no statistically significant difference by preparation method or assay (phase II laboratory testing; figure 1) .
Discussion. After the introduction of the AmpliPrep/ TaqMan assay, 77% of patients with previously undetectable HIV-1 who were receiving stable ART had detectable HIV-1 RNA levels. Comparison with results from the previous year suggested that the increased frequency of detectability was an artifact. Independent quality-assurance testing of paired plasma samples indicated that differences in the assay alone did not cause this increase in HIV-1 RNA detection and implicated frozen plasma storage and shipment in the primary PPT as the cause. An increase in the frequency of detection of HIV-1 RNA was observed for every assay tested with plasma that was frozen and thawed in the primary PPT (AMPLICOR with or without virion centrifugation and AmpliPrep/TaqMan). Transferring plasma from a centrifuged PPT into a secondary tube before freezing and shipment corrected the high proportion of detectable HIV-1 RNA from patients with stably suppressed HIV-1 RNA levels.
Previous studies hypothesized that the freezing and thawing of platelets and other cellular elements leads to "leakage" of HIV nucleic acid across the polyethylene gel barrier that separates cells from the acellular plasma in PPTs after centrifugation [7] [8] [9] [10] [11] . One report suggested that concentrating the virions in plasma taken from a primary PPT that has been frozen and thawed prior to HIV-1 RNA assay performance might minimize this leakage [9] ; this was based on the hypothesis that "naked" HIV nucleic acid released in the supernatant from cells lysed by freezing and thawing would be discarded after centrifugation. The effect of concentrating the virions in plasma was tested, because additional processing at the laboratory, rather than at the clinic collection site, might be advantageous for some clinics. However, virion concentration did not completely eliminate the artifactual detection of HIV-1 RNA. This suggests that at least some of the HIV-1 nucleic acid released by the freezing and thawing of primary PPTs may be located in structures that pellet on centrifugation (such as HIV virions or cores) or that enough free nucleic acid to be amplified is present in the small volume of residual supernatant that overlays the pellet.
Even an artifactual increase in HIV-1 RNA level that is large enough only to reach the lower limit of detection may mean the difference between considering a patient as having a treatment response or a treatment failure; this is problematic for trial end points and has important clinical implications [4] [5] [6] . Proper laboratory procedures are essential for minimizing artifacts; these procedures include proper maintenance and decontamination of automated instruments used for sample preparation, amplification, detection, and calculation of results. This study indicates that clinicians should be aware of specimenpreparation procedures and should not send plasma frozen in primary PPTs for HIV-1 RNA detection assays. In addition, testing laboratories should reject primary PPTs received for any HIV-1 RNA assay. Some clinics may not have facilities that allow for plasma to be placed in a separate tube after centrifugation of the primary PPT. In such circumstances, clinicians should refer patients to a laboratory that has the capacity for proper specimen processing after the collection of a blood sample, to avoid spuriously detectable viral loads.
